Plusssz Junior Actions

How long did you take this medication to work?

Actions of Plusssz Junior in details

The action of the drug on the human body is called Pharmacodynamics in Medical terminology. To produce its effect and to change the pathological process that is happening the body and to reduce the symptom or cure the disease, the medicine has to function in a specific way. The changes it does to the body at cellular level gives the desired result of treating a disease. Drugs act by stimulating or inhibiting a receptor or an enzyme or a protein most of the times. Medications are produced in such a way that the ingredients target the specific site and bring about chemical changes in the body that can stop or reverse the chemical reaction which is causing the disease.

Plusssz Junior binds to Nicotinate D-ribonucleotide phyrophsopate phosphoribosyltransferase, Nicotinic acid phosphoribosyltransferase, Nicotinate N-methyltransferase and the Plusssz Junior receptor. Plusssz Junior is the precursor to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are vital cofactors for dozens of enzymes. The mechanism by which Plusssz Junior exerts its lipid lowering effects is not entirely understood, but may involve several actions, including a decrease in esterification of hepatic triglycerides. Plusssz Junior treatment also decreases the serum levels of apolipoprotein B-100 (apo B), the major protein component of the VLDL (very low-density lipoprotein) and LDL fractions.

How should I take Plusssz Junior?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Plusssz Junior is sometimes taken at bedtime with a low-fat snack. Follow your doctor's instructions.

Plusssz Junior can cause certain side effects, such as flushing (warmth, itching, redness, or tingly feeling under your skin). These effects can be made worse if you drink alcohol or hot beverages shortly after you take Plusssz Junior. These effects should disappear over time as you keep taking the medication.

Take Plusssz Junior with a full glass of cold or cool water. Taking the medication with a hot drink may increase your risk of side effects such as flushing.

Do not crush, chew, break, or open an extended-release tablet or capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time.

Plusssz Junior extended-release tablets and capsules contain higher strengths of the medicine than the regular Plusssz Junior tablets. Take only the dose that is correct for the type of Plusssz Junior tablet or capsule you are using.

Plusssz Junior can cause you to have unusual results with certain medical tests (urine tests). Tell any doctor who treats you that you are using Plusssz Junior.

If you stop taking Plusssz Junior for any length of time, talk with your doctor before starting the medication again. You may need to restart the medication at a lower dose.

While using Plusssz Junior, you may need blood tests at your doctor's office. Your kidney or liver function may also need to be checked. Visit your doctor regularly.

Plusssz Junior is only part of a complete program of treatment that may also include diet, exercise, weight control, and other medications. Follow your diet, medication, and exercise routines very closely.

Store at room temperature away from moisture and heat.

Plusssz Junior administration

Administration of drug is important to know because the drug absorption and action varies depending on the route and time of administration of the drug. A medicine is prescribed before meals or after meals or along with meals. The specific timing of the drug intake about food is to increase its absorption and thus its efficacy. Few work well when taken in empty stomach and few medications need to be taken 1 or 2 hrs after the meal. A drug can be in the form of a tablet, a capsule which is the oral route of administration and the same can be in IV form which is used in specific cases. Other forms of drug administration can be a suppository in anal route or an inhalation route.

Administer with food. To attenuate flushing symptoms, may premedicate with aspirin 30 minutes before dose; avoid ingestion of alcohol, hot or spicy foods/liquids concurrently with Plusssz Junior. May also use other nonsteroidal anti-inflammatory drugs to prevent flushing according to the manufacturer.

Niaspan: Administer at bedtime after a low-fat snack. Two of the 500 mg and one of the 1,000 mg tablet strengths are interchangeable, but three of the 500 mg and two of the 750 mg tablet strengths are not interchangeable. When switching from IR tablet, initiate Niaspan with the recommended titration schedule. If therapy is interrupted for an extended period, dose should be retitrated.

Long-acting forms should not be crushed, broken, or chewed. Slo-Plusssz Junior may be broken along the score line. Do not substitute long-acting forms for immediate release ones.

Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER formulations should be swallowed whole. Do not chew or crush. If safety and efficacy of Plusssz Junior can be effectively monitored, no change in formulation or administration is required after bariatric surgery. Bariatric vitamin supplementation is recommended on a lifelong basis after surgery; consider integration of daily Plusssz Junior regimen into the bariatric vitamin regimen.

Plusssz Junior pharmacology

Pharmacokinetics of a drug can be defined as what body does to the drug after it is taken. The therapeutic result of the medicine depends upon the Pharmacokinetics of the drug. It deals with the time taken for the drug to be absorbed, metabolized, the process and chemical reactions involved in metabolism and about the excretion of the drug. All these factors are essential to deciding on the efficacy of the drug. Based on these pharmacokinetic principles, the ingredients, the Pharmaceutical company decides dose and route of administration. The concentration of the drug at the site of action which is proportional to therapeutic result inside the body depends on various pharmacokinetic reactions that occur in the body.

Mechanism of Action

The mechanism by which Plusssz Junior alters lipid profiles has not been well defined. It may involve several actions including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity, which may increase the rate of chylomicron triglyceride removal from plasma. Plusssz Junior decreases the rate of hepatic synthesis of VLDL and LDL, and does not appear to affect fecal excretion of fats, sterols, or bile acids.



Due to extensive and saturable first-pass metabolism, Plusssz Junior concentrations in the general circulation are dose dependent and highly variable. Time to reach the maximum Plusssz Junior plasma concentrations was about 5 hours following Plusssz Junior extended-release tablets. To reduce the risk of gastrointestinal (GI) upset, administration of Plusssz Junior extended-release tablets with a low-fat meal or snack is recommended.

Single-dose bioavailability studies have demonstrated that the 500 mg and 1000 mg tablet strengths are dosage form equivalent but the 500 mg and 750 mg tablet strengths are not dosage form equivalent.


The pharmacokinetic profile of Plusssz Junior is complicated due to extensive first-pass metabolism that is dose-rate specific and, at the doses used to treat dyslipidemia, saturable. In humans, one pathway is through a simple conjugation step with glycine to form nicotinuric acid (NUA). NUA is then excreted in the urine, although there may be a small amount of reversible metabolism back to Plusssz Junior. The other pathway results in the formation of nicotinamide adenine dinucleotide (NAD). It is unclear whether nicotinamide is formed as a precursor to, or following the synthesis of, NAD. Nicotinamide is further metabolized to at least N-methylnicotinamide (MNA) and nicotinamide-N-oxide (NNO). MNA is further metabolized to two other compounds, N-methyl-2-pyridone-5-carboxamide (2PY) and N-methyl-4-pyridone-5-carboxamide (4PY). The formation of 2PY appears to predominate over 4PY in humans. At the doses used to treat hyperlipidemia, these metabolic pathways are saturable, which explains the nonlinear relationship between Plusssz Junior dose and plasma concentrations following multiple-dose Plusssz Junior extended-release tablet administration.

Nicotinamide does not have hypolipidemic activity; the activity of the other metabolites is unknown.


Following single and multiple doses, approximately 60 to 76% of the Plusssz Junior dose administered as Plusssz Junior extended-release tablets was recovered in urine as Plusssz Junior and metabolites; up to 12% was recovered as unchanged Plusssz Junior after multiple dosing. The ratio of metabolites recovered in the urine was dependent on the dose administered.

Pediatric Use

No pharmacokinetic studies have been performed in this population (≤ 16 years).

Geriatric Use

No pharmacokinetic studies have been performed in this population (> 65 years).

Renal Impairment

No pharmacokinetic studies have been performed in this population. Plusssz Junior extended-release tablets should be used with caution in patients with renal disease.

Hepatic Impairment

No pharmacokinetic studies have been performed in this population. Active liver disease, unexplained transaminase elevations and significant or unexplained hepatic dysfunction are contraindications to the use of Plusssz Junior extended-release tablets.


Steady-state plasma concentrations of Plusssz Junior and metabolites after administration of Plusssz Junior extended-release tablets are generally higher in women than in men, with the magnitude of the difference varying with dose and metabolite. This gender difference observed in plasma levels of Plusssz Junior and its metabolites may be due to gender-specific differences in metabolic rate or volume of distribution. Recovery of Plusssz Junior and metabolites in urine, however, is generally similar for men and women, indicating that absorption is similar for both genders.

Drug Interactions


Plusssz Junior did not affect fluvastatin pharmacokinetics.


When Plusssz Junior extended-release tablets 2000 mg and lovastatin 40 mg were co-administered, Plusssz Junior extended-release tablets increased lovastatin Cmax and AUC by 2% and 14%, respectively, and decreased lovastatin acid Cmax and AUC by 22% and 2%, respectively. Lovastatin reduced Plusssz Junior extended-release tablet bioavailability by 2 to 3%.


When Plusssz Junior extended-release tablets 2000 mg and simvastatin 40 mg were co-administered, Plusssz Junior extended-release tablets increased simvastatin Cmax and AUC by 1% and 9%, respectively, and simvastatin acid Cmax and AUC by 2% and 18%, respectively. Simvastatin reduced Plusssz Junior extended-release tablet bioavailability by 2%.

Bile Acid Sequestrants

An in vitro study was carried out investigating the Plusssz Junior-binding capacity of colestipol and cholestyramine. About 98% of available Plusssz Junior was bound to colestipol, with 10 to 30% binding to cholestyramine.


The results of a survey conducted on for Plusssz Junior are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Plusssz Junior. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported administration

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 All Rights Reserved